Fintel reports that on July 16, 2025, B of A Securities downgraded their outlook for Centene (NYSE:CNC) from Neutral to ...

However, for Q1 2025, Centene Corporation (NYSE:CNC) stated that premium and service revenues rose by 17% to $42.5 billion ...

Investing.com -- Shares of Centene (NYSE:CNC) plunged more than 32% in premarket trading Wednesday after the company pulled its 2025 guidance, citing unexpectedly poor risk adjustment results in ...

The Clayton-based health giant is likely to face increased challenges as federal government tightens Medicaid eligibility and ...

On June 2, an analyst from Barclays downgraded Centene Corporation’s (NYSE:CNC) rating from Overweight to Equal-Weight and lowered its price target from $84 to $65. The downgrade follows Centene ...

Investing.com - UBS downgraded Centene (NYSE:CNC) stock rating from Buy to Neutral on Wednesday, slashing its price target to $45.00 from $80.00 following the healthcare company’s withdrawal of ...

Jefferies downgraded Centene (CNC) to Underperform from Hold with a price target of $52, down from $68. After analysis of Affordable Care Act Exchange data, the firm sees potential for ...

As of March 9, 2023, the average one-year price target for Centene is $93.90. The forecasts range from a low of $79.79 to a high of $115.50. The average price target represents an increase of 40. ...

Humana, Elevance, Centene downgraded days before second-quarter earnings kickoff Major payers are facing downgrades amid rising Medicare Advantage and commercial cost pressures. Published July 13 ...

This revision was in response to Centene's slight increase in its 2024 EPS guidance by approximately 1.5%, despite a roughly 0.40% miss in the Medicaid Medical Loss Ratio.